Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesClearmind Medicine Inc. Common Shares

Clearmind Medicine Inc. Common Shares

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
5.6661 USD 0.08 ( 1.47%)
Last update at 2026-11-09T18:18:00Z
VOLUME
3765
Market Cap
2.78M

Momentum Score

…

Clearmind Medicine Inc., a clinical stage pharmaceutical company, develops novel psychedelic medicines to treat under-served health problems. The company develops treatments for alcohol use disorders, binge drinking, and eating disorders, as well as weight loss, obesity, and metabolic syndrome, anxiety disorders, post-traumatic stress disorder, depression, and treatment resistant depression. It develops MEAI compound for the treatment of alcohol use disorder, obesity, and metabolic disorders, as well as an alcohol substitute consumer product; and CM-CMND-001 which is in Phase I/IIa clinical trial for the treatment of alcohol use disorder. In addition, the company has a strategic collaboration with SciSparc Ltd., Yissum Research Development Company of the Hebrew University of Jerusalem, Polyrizon Ltd., and NeuroThera Labs Inc. The company was formerly known as Cyntar Ventures Inc. and changed its name to Clearmind Medicine Inc. in March 2021. The company was incorporated in 2017 and is headquartered in Vancouver, Canada.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
5.40
Low
5.77
High
52 Week Price Range
0.83
Low
524.00
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Clearmind Medicine Inc. is a clinical-stage biopharmaceutical company developing psychedelic-derived therapies for neuropsychiatric disorders including addiction and mood disorders. Long-term growth drivers include clinical trial progress, regulatory acceptance of psychedelic-based treatments, and expanded funding and market demand for mental-health therapeutics, which may benefit investors seeking exposure to this emerging area.
Material risks are typical of small biotech: early-stage clinical and regulatory uncertainty, high cash burn and potential dilution, limited commercial track record, and low liquidity that could increase share volatility.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
5.58
Dividend Yield
-
Revenue TTM
0.00M
Revenue Per Share
-
Gross Profit TTM
0.00M
Debt / Equity
1.49
ROE
-114.61%
Net Debt
-2.14M
ROCE
-315.87%
Diluted EPS TTM
-57.79

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-10-31 2024-10-31 2023-10-31 2022-12-31 2022-10-31
Type yearly yearly yearly yearly yearly
Date 2025-10-31 2024-10-31 2023-10-31 2022-12-31 2022-10-31
Income before tax -3.79M -6.79M -11.83M -9.37M -9.89M
Net income -3.86M -7.31M -11.85M -9.41M -9.93M
Selling general administrative 3.57M 3.26M 6.60M 5.43M 5.43M
Selling and marketing expenses - 1.09M 0.18M - -
Gross profit -0.05M -0.07M -0.08M - -0.12M
Reconciled depreciation 0.05M 0.05M 0.06M 0.11M 0.11M
Ebit -3.77M -6.74M -11.83M -8.53M -9.86M
Ebitda -3.72M -6.67M -11.75M -8.42M -9.75M
Depreciation and amortization 0.05M 0.07M 0.08M 0.11M 0.12M
Operating income -5.67M -8.00M -8.67M -8.53M -9.00M
Other operating expenses 5.67M 8.00M 8.67M 8.53M 9.00M
Interest expense 0.02M 0.05M 0.01M 0.02M 0.02M
Tax provision 0.07M 0.38M 0.02M 0.04M 0.04M
Interest income 0.13M 0.27M 0.07M - 0.00M
Net interest income 0.11M 0.24M 0.06M -0.02M -0.02M
Income tax expense 0.07M 0.53M 0.02M 0.04M 0.04M
Total revenue 0.00M 0.00M 0.00M 0.00M 0.00M
Total operating expenses 5.62M 7.93M 8.59M 8.53M 8.88M
Cost of revenue 0.05M 0.07M 0.08M - 0.12M
Total other income expense net 1.88M 1.21M -3.16M -0.84M -0.88M
Net income from continuing ops -3.86M -5.25M -8.62M -9.41M -9.41M
Net income applicable to common shares - - - -9.41M -9.41M
Breakdown 2025-10-31 2024-10-31 2023-12-31 2023-10-31 2022-12-31
Type yearly yearly yearly yearly yearly
Date 2025-10-31 2024-10-31 2023-12-31 2023-10-31 2022-12-31
Total assets 6.08M 10.10M 5.95M 5.95M 1.13M
Intangible assets 0.10M 0.15M - 0.16M 0.18M
Other current assets 0.04M 0.06M 0.06M 0.04M 0.02M
Total liab 4.89M 5.77M 4.97M 4.97M 2.64M
Total stockholder equity 1.19M 4.33M 0.98M 0.98M -1.51M
Deferred long term liab - - - - 0.27M
Other current liab 2.43M 4.97M 4.35M 4.35M 0.68M
Common stock 26.40M 33.64M 17.13M 17.13M 9.15M
Capital stock 26.40M 24.17M 17.13M 17.13M 9.15M
Retained earnings -27.88M -33.44M -18.77M -18.77M -13.85M
Good will - - - -0.00M -
Other assets - - - 0.02M 0.29M
Cash 3.92M 9.15M 5.43M 5.43M 0.18M
Total current liabilities 4.89M 5.75M 4.97M 4.97M 2.64M
Net debt -2.14M -9.08M -5.43M -5.43M -0.12M
Short term debt 1.78M 0.05M - - 0.05M
Short long term debt 1.76M - - - -
Short long term debt total 1.78M 0.07M - - 0.05M
Other stockholder equity 2.69M 4.15M 2.64M 2.64M 2.54M
Property plant equipment - - - - 0.07M
Total current assets 5.95M 9.87M 5.79M 5.79M 0.59M
Net tangible assets - - - - -1.69M
Short term investments 1.66M 0.40M 0.09M 0.09M 0.26M
Net receivables 0.32M 0.25M 0.24M 0.24M 0.13M
Inventory - - -0.02M -0.04M -
Accounts payable 0.68M 0.73M 0.62M 0.62M 1.91M
Accumulated other comprehensive income -0.02M -0.03M -0.02M -0.02M 0.64M
Non currrent assets other 0.02M 0.01M 0.04M -0.01M 0.29M
Non current assets total 0.14M 0.23M 0.16M 0.16M 0.53M
Capital lease obligations 0.02M 0.05M 0.00M 0.00M 0.05M
Breakdown 2025-10-31 2024-10-31 2023-10-31 2022-12-31 2022-10-31
Type yearly yearly yearly yearly yearly
Date 2025-10-31 2024-10-31 2023-10-31 2022-12-31 2022-10-31
Investments -0.53M -0.24M -0.03M -0.01M -0.01M
Change to liabilities - - - 1.25M 1.25M
Total cashflows from investing activities -0.54M -0.33M -0.03M -0.01M -0.01M
Net borrowings 2.21M -0.04M -0.04M -0.08M -0.08M
Total cash from financing activities 2.62M 8.71M 11.66M 0.70M 0.69M
Change to operating activities - - - 0.41M 0.41M
Net income -3.86M -7.31M -8.62M -9.41M -9.36M
Change in cash -2.65M 1.60M 5.30M -4.42M -4.40M
Begin period cash flow 6.57M 7.56M 0.13M 4.60M 4.57M
End period cash flow 3.92M 9.15M 5.43M 0.18M 0.17M
Total cash from operating activities -4.73M -6.76M -6.30M -5.08M -5.06M
Issuance of capital stock 0.00M 2.19M 11.12M 0.80M 0.80M
Depreciation 0.05M 0.07M 0.06M 0.11M 0.11M
Other cashflows from investing activities -0.01M 0.05M -0.03M - -0.01M
Dividends paid - - - 0.00M 0.00M
Change to inventory - - 0.15M - -0.03M
Change to account receivables 0.02M 0.09M -0.15M 0.03M 0.03M
Other cashflows from financing activities 0.58M 5.71M 0.59M -0.02M 0.12M
Change to netincome - - - 2.53M 2.53M
Capital expenditures 0.00M 0.00M 0.00M 0.01M 0.01M
Change in working capital -0.04M -0.18M -0.97M 1.69M 1.68M
Stock based compensation 0.81M 1.39M 0.37M 1.65M 1.64M
Other non cash items -1.76M -0.87M 3.21M 0.84M 0.83M
Free cash flow -4.73M -6.76M -6.30M -5.09M -5.06M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to EBITDA (x)
CMND
Clearmind Medicine Inc. Common Shares		 0.08
1.47%		 5.67 - - - 0.22 -0.79
NVO
Novo Nordisk A/S		 1.03
2.56%		 41.34 41.58 31.15 2.13 32.99 4.70
VRTX
Vertex Pharmaceuticals Inc		 1.49
0.27%		 548.58 30.22 24.27 10.36 6.50 24.66
REGN
Regeneron Pharmaceuticals Inc		 18.16
2.01%		 922.51 29.07 20.12 7.57 3.82 19.42
ARGNF
argenx SE		 -
-%		 900.30 45.77 31.25 13.84 7.12 36.06

Profile*

Clearmind Medicine Inc. Common Shares

Clearmind Medicine Inc., a clinical stage pharmaceutical company, develops novel psychedelic medicines to treat under-served health problems. The company develops treatments for alcohol use disorders, binge drinking, and eating disorders, as well as weight loss, obesity, and metabolic syndrome, anxiety disorders, post-traumatic stress disorder, depression, and treatment resistant depression. It develops MEAI compound for the treatment of alcohol use disorder, obesity, and metabolic disorders, as well as an alcohol substitute consumer product; and CM-CMND-001 which is in Phase I/IIa clinical trial for the treatment of alcohol use disorder. In addition, the company has a strategic collaboration with SciSparc Ltd., Yissum Research Development Company of the Hebrew University of Jerusalem, Polyrizon Ltd., and NeuroThera Labs Inc. The company was formerly known as Cyntar Ventures Inc. and changed its name to Clearmind Medicine Inc. in March 2021. The company was incorporated in 2017 and is headquartered in Vancouver, Canada.

1220 West 6th Avenue, Vancouver, BC, Canada, V6H 1A5

973 536 1016

https://www.clearmindmedicine.com

Name Title Year Born
Dr. Adi Zuloff-Shani Ph.D. Chief Exec. Officer 1970
Mr. Alan Mark Rootenberg B.Com., B.Comm, C.A., CPA CFO & Director 1952
Prof. Mark Haden VP of Bus. Devel. 1954
Mr. Gilad Babchuk Head of Strategy & Communication NA
Dr. Adi Zuloff-Shani Ph.D. Chief Executive Officer 1969
Mr. Alan Mark Rootenberg B.Com., B.Comm, C.A., C.P.A. Chief Financial Officer 1952
Prof. Mark Haden Vice President of Business Development 1955
Dr. Adi Zuloff-Shani Ph.D. Chief Executive Officer 1967
Mr. Alan Mark Rootenberg B.Com., B.Comm, C.A., CPA Chief Financial Officer 1952
Prof. Mark Haden M.S.W. Vice President of Business Development 1953

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

GFR
CAD 10.94
+37.96%
MOON
CAD 4.90
+11.11%
UCU
CAD 2.37
+10.75%
ANRG
CAD 1.90
+10.47%
EPRX
CAD 10.71
+10.30%
DIV
CAD 3.77
-7.37%
CSU
CAD 3281.97
-6.93%
LMN
CAD 26.62
-5.23%
TOI
CAD 99.75
-4.80%
GRZ
CAD 5.05
-4.72%

Equity Sectors*

  • Basic Materials

    +4.21%

  • Communication Services

    -0.63%

  • Consumer Cyclical

    +1.12%

  • Consumer Defensive

    +0.09%

  • Energy

    +1.91%

  • Financial Services

    +1.63%

  • Healthcare

    +1.49%

  • Industrials

    +3.56%

  • Real Estate

    +0.66%

  • Technology

    +1.84%

  • Utilities

    +1.24%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…